Sage Therapeutics Provides Data from the P-II (LIGHTWAVE) Trial of Dalzanemdor to Treat Mild Cognitive Impairment and Dementia in Alzheimer’s Disease
Shots:
- Sage has reported topline data from the P-II (LIGHTWAVE) study assessing the safety & efficacy of dalzanemdor vs PBO for treating patients (n=174) with mild cognitive impairment (MCI) or dementia associated with Alzheimer’s Disease (AD), for 12wks.
- The study found no significant difference on the WAIS-IV Coding Test score at D84 (1EP) and RBANS or MoCA total scores (exploratory endpoints). Safety profile was well-tolerated, with mild to moderate TEAEs
- The company will not continue with the trial. Topline data from its other P-II (DIMENSION) trial of dalzanemdor for cognitive impairment due to Huntington’s disease is anticipated Q4’24
Ref: Sage Therapeutics | Image: Sage Therapeutics
Related News:- Cybrexa Therapeutics Doses the First Patient with CBX-12 Under P-II Study for Treating Ovarian Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.